Skip to main content
SINSIN PHARMACEUTICAL Co., LTD. logo

SINSIN PHARMACEUTICAL Co., LTD. — Investor Relations & Filings

Ticker · 002800 ISIN · KR7002800001 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2021-03-16 Audit Report / Informat…
Country KR South Korea
Listing KO 002800

About SINSIN PHARMACEUTICAL Co., LTD.

https://sinsin2002.tradekorea.com/

Sinsin Pharmaceutical Co., Ltd. is a pharmaceutical company that specializes in the development, manufacturing, and marketing of over-the-counter (OTC) medicines for external use. The company's core product portfolio centers on topical anti-inflammatory and analgesic drugs, including its widely recognized brand of pain relief patches, "SINSIN PAS," alongside various sprays and lotions. The company also produces a diverse range of consumer healthcare items such as mosquito repellents, wound care products like surgical plasters and healing bands, anti-mycotic treatments, and other dermatological preparations for both domestic and overseas markets.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, financial highlights (assets, liabilities, profit/loss), and auditor information for the fiscal year. While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report (AR). In the context of Korean regulatory filings (DART/KIND), this specific format is a standard disclosure announcement regarding the receipt and submission of the audit report. FY 2020
2021-03-16 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Sinsin Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), and financial statements (balance sheets and income statements) for the 58th fiscal year. This type of document is standard for providing shareholders with the necessary information to vote on company matters, including director appointments and financial approvals, which falls under the category of Proxy Solicitation & Information Statement.
2021-03-05 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains information about the meeting date, agenda items (such as approval of financial statements), and instructions for electronic voting. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2021-03-05 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by ShinShin Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2021-02-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Shinshin Pharmaceutical) announcing a significant change in financial results (revenue or profit/loss structure exceeding 30%). This is a standard regulatory disclosure requirement in Korea (DART system) for listed companies to report preliminary financial results before the final audit is completed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the Earnings Release (ER) category. FY 2020
2021-01-25 Korean
불성실공시법인지정(공시번복)
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement regarding the designation of the company as an 'unfaithful disclosure corporation' (불성실공시법인) due to a disclosure reversal (공시번복) concerning a contract termination. This is a formal regulatory notice regarding compliance and penalties, which does not fit into financial reporting or corporate governance categories, making it a standard regulatory filing.
2021-01-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.